NECTIN4 and neoplasm: Indeed, enfortumab vedotin, a kind of antibody–drug conjugates (ADCs) which targets NECTIN4, has been reported to suppress NECTIN4-overexpressing tumor cell growth and further evaluated preclinically in human breast, bladder, pancreas, lung, and urothelial cancers [24,25,26,27].